Skip To Main Content
Bryn Nelson on Muck Rack

Bryn Nelson

Verified
Seattle
As seen in: CNN, CNN en Español, Medium, The New York Times, BBC Mundo, Color Research & Application, Daily Mail, Nature, The Guardian, The Independent (UK) and
Science writer & author of Flush. No longer active on X due to the aggressive disinformation & anti-Semitism; find me here instead: @seattlebryn.bsky.social
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bryn

Contact Bryn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

New progress in addressing cancer pain

|
By Bryn Nelson Verified, William Faquin MD
| Wiley Online Library Verified
Although pain has long been recognized as a common feature of both cancer and cancer treatments, efforts to recognize and resolve it have faltered in part because of fragmented care, a lack of objective measurements, and limited options for mitigating moderate to severe pain.
Open in Who Shared Issue with article?

Much promise, scant evidence for multicancer early detection tests

|
By Bryn Nelson Verified, William Faquin MD
| Wiley Online Library Verified
In a provocative ad that debuted during last February’s Super Bowl, San Francisco–based telehealth company Hims & Hers asserted, “Rich people live longer,” and then suggested how everyone else might “get the best of everything” to boost their own longevity.
Open in Who Shared Issue with article?

Predictive Machine Learning for Difficult-to-Treat Rheumatoid Arthritis

|
By Bryn Nelson Verified
| The Rheumatologist Verified
According to recent estimates, roughly 20% of patients with rheumatoid arthritis (RA) are at risk of failing multiple treatments.1 No risk prediction tools yet exist for this multi-treatment failure disease state, known as difficult-to-treat RA (D2T-RA), leaving rheumatologists little guidance on which patients are at highest risk for disease progression.
Open in Who Shared Issue with article?
See all 258 licensed articles (264 Total)